Belfast · Northern Ireland
TheBELFAST HERALDLocal knowledge. National perspective.
Retrospective archiveHistorical reports were compiled from linked contemporaneous sources. Dates refer to the events covered.How the archive works
HealthPremium archive

Limited-size clinical trial in Johannesburg suggests that the Oxford–AstraZeneca COVID-19 vaccine is weak against the 501.V2 variant of SARS-CoV-2

A limited-size clinical trial in Johannesburg suggests that the Oxford–AstraZeneca COVID-19 vaccine is weak against the 501.V2 variant of SARS-CoV-2.

By Belfast Herald Newsdesk1 min read

Herald Premium Archive

This report is for subscribers

Sign in or choose a plan to read this report and the complete Premium retrospective archive.

HealthLimited-size clinical trial in Johannesburg suggests that the Oxford–AstraZeneca COVID-19 vaccine is weak against the 501.V2 variant of SARS-CoV-2

A limited-size clinical trial in Johannesburg suggests that the Oxford–AstraZeneca COVID-19 vaccine is weak against the 501.V2 variant of SARS-CoV-2.

View Premium plansBrowse free archive reports